Syntara's Final Phase 2 Results Underscore Safety, Tolerability, Says Euroz Hartleys, Shares Jump 19%

MT Newswires Live

2025/09/30

Syntara's (ASX:SNT) final phase 2 results for its myelofibrosis drug candidate SNT-5505 have shown that the drug was safe and well-tolerated, according to a Tuesday note from Euroz Hartleys.

According to the note, the drug candidate has shown symptom improvement as well as spleen volume reduction in the trial.

The research firm also noted that the company has appointed several global experts to a new strategic and clinical advisory board, including Adam Craig, former chief executive of BioPharma.

Euroz Hartleys has maintained its speculative buy rating on Syntara with a price target of AU$0.22.

The company's shares rose almost 19% in recent Tuesday trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2571213318"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571213318\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571213318?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 14:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571213318","market":"sg","top_or_hot":-1,"title":"Syntara's Final Phase 2 Results Underscore Safety, Tolerability, Says Euroz Hartleys, Shares Jump 19%","media":"MT Newswires Live","content":"<html><body><p> Syntara's (ASX:SNT) final phase 2 results for its myelofibrosis drug candidate SNT-5505 have shown that the drug was safe and well-tolerated, according to a Tuesday note from <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>According to the note, the drug candidate has shown symptom improvement as well as spleen volume reduction in the trial.</p><p>The research firm also noted that the company has appointed several global experts to a new strategic and clinical advisory board, including Adam Craig, former chief executive of BioPharma.</p><p>Euroz Hartleys has maintained its speculative buy rating on Syntara with a price target of AU$0.22.</p><p>The company's shares rose almost 19% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Syntara's Final Phase 2 Results Underscore Safety, Tolerability, Says Euroz Hartleys, Shares Jump 19%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSyntara's Final Phase 2 Results Underscore Safety, Tolerability, Says Euroz Hartleys, Shares Jump 19%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-30 14:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Syntara's (ASX:SNT) final phase 2 results for its myelofibrosis drug candidate SNT-5505 have shown that the drug was safe and well-tolerated, according to a Tuesday note from <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys.</p><p>According to the note, the drug candidate has shown symptom improvement as well as spleen volume reduction in the trial.</p><p>The research firm also noted that the company has appointed several global experts to a new strategic and clinical advisory board, including Adam Craig, former chief executive of BioPharma.</p><p>Euroz Hartleys has maintained its speculative buy rating on Syntara with a price target of AU$0.22.</p><p>The company's shares rose almost 19% in recent Tuesday trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNT.AU","symbol_name":"Syntara Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2571213318","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571213318","pubTimestamp":1759212538,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Syntara's  final phase 2 results for its myelofibrosis drug candidate SNT-5505 have shown that the drug was safe and well-tolerated, according to a Tuesday note from Euroz Hartleys.According to the note, the drug candidate has shown symptom improvement as well as spleen volume reduction in the trial.The research firm also noted that the company has appointed several global experts to a new strategic and clinical advisory board, including Adam Craig, former chief executive of BioPharma.Euroz Hartleys has maintained its speculative buy rating on Syntara with a price target of AU$0.22.The company's shares rose almost 19% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNT.AU":"Syntara Ltd","BK7096":"制药"},"translate_title":"Euroz Hartleys表示，Syntara第二阶段的最终结果强调了安全性和耐受性，股价上涨19%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNT.AU":1},"content_text":"Syntara's (ASX:SNT) final phase 2 results for its myelofibrosis drug candidate SNT-5505 have shown that the drug was safe and well-tolerated, according to a Tuesday note from Euroz Hartleys.According to the note, the drug candidate has shown symptom improvement as well as spleen volume reduction in the trial.The research firm also noted that the company has appointed several global experts to a new strategic and clinical advisory board, including Adam Craig, former chief executive of BioPharma.Euroz Hartleys has maintained its speculative buy rating on Syntara with a price target of AU$0.22.The company's shares rose almost 19% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}